(11-acetyl-8-carbamoyloxymethyl-4-formyl-l4-oxa-1,11 -diaza tetracyclo[7.4.1.O2,7O10,12]tetradeca-2,4,6-trien-6,9-diyl diacetate), a new sub stituted dihydrobenzoxazine, has potent cytotoxic and antitumor effects on murine and human tumors in vivo and in vitro, and forms interstrand DNA-DNA and DNAprotein cross-links after being activated in the cytoplasm.
Abstract-FK973
(11-acetyl-8-carbamoyloxymethyl-4-formyl-l4-oxa-1,11 -diaza tetracyclo [7. 4.1.O2,7O10,12]tetradeca-2,4,6-trien-6,9-diyl diacetate), a new sub stituted dihydrobenzoxazine, has potent cytotoxic and antitumor effects on murine and human tumors in vivo and in vitro, and forms interstrand DNA-DNA and DNAprotein cross-links after being activated in the cytoplasm.
In this study, the mech anism(s) by which FK973 is activated in the cytoplasm of in vitro cultured murine L1210 leukemia cells were studied using compounds that affect monoamine oxidase. When the cells were incubated with an antitumor drug and the compounds, tranylcy promine, benzylamine, phenylethylamine and tyramine of the many compounds tested reduced the cytotoxicity of FK973, but not that of mitomycin C or cisplatin. These compounds also suppressed the formation of interstrand DNA-DNA cross links with FK973 in the cells, but did not suppress cross-links with mitomycin C or cisplatin.
The incorporation of 14C-FK973 into the cells was not affected by these compounds.
The results suggest that FK973 is activated by some drug-metabolic system(s) in the cytoplasm to form interstrand DNA-DNA cross-links, and induces cytotoxicity against the cells. This activation of FK973 in the cytoplasm is discussed in connection with the drug-metabolic system(s) in relation to the structures of the compounds.
FK973 (11 -acetyl-8- (1) (2) (3) (4) (5) . In our previous study, we showed that FK973 had strong in vitro and in vivo activities against a wide variety of tumors (6) . Furthermore, we showed that FK973 formed time-dependent interstrand DNA-DNA and DNA-protein cross-links (7) and arrested cells at the G2 phase in cultured murine L1210 leukemia cells (8) . When the isolated nuclei of L1210 were exposed to FK973, the substance did not form detectable interstrand DNA-DNA cross links (7) . Thus, FK973 may be gradually ac tivated in the cytoplasm after the drug is in corporated, and the activated FK973 forms both types of cross-links. Mitomycin C (MMC) was reported to form interstrand DNA-DNA and DNA-protein cross-links after being easily reduced by NADPH-de pendent cytochrome P-450 reductase and xanthine oxidase in the cytoplasm (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . On the other hand, cisplatin (CDDP) forms these cross-links in the cells directly (19, 20) . However, the mechanism(s) of the activation of FK973 in the cytoplasm has not been defined. We attempted to clarify the possible mechanism(s) of its activation in cells using many compounds that act on drug metab olism. It is known that monoamine oxidase (MAO) is important for drug metabolism, since MAO inhibitors interfere with the me tabolic degradation of cocaine (21) Materials and Methods Drugs: FK973 (Fig. 1 ) and 14C-FK973 (specific activity, 796 kBq/mg) were pre pared in the Fujisawa Research Laboratories. M M C (Fig. 1) was purchased from Kyowa Hakko Co., Ltd., Tokyo, Japan; and CDDP was from Sigma Chemical Company, St. Louis, MO, U.S.A. Tranylcypromine hydro chloride, nialamide, iproniazid phosphate and pargyline hydrochloride were purchased from Sigma Chemical Company, St. Louis MO, U.S.A. Benzylamine hydrochloride, phenyl ethylamine hydrochloride, tyramine hydro chloride and aniline hydrochloride were from Nacalal Tesque Co., Ltd., Kyoto, Japan; and phenylpropylamine and phenylbutylamine were from Aldrich Chemical Co., Inc., Mil waukee, WI, U.S.A. FK973, 14C-FK973 and CDDP were dissolved in phosphate-buffered saline (PBS). MMC was dissolved in distilled water. Nialamide was dissolved in dimethyl sulfoxide. Phenylpropylamine and phenyl butylamine were dissolved in 1 N hydro chloric acid and diluted with PBS. The other compounds were dissolved in PBS. All com pounds were diluted with the culture medium.
Cell culture: Murine L1210 leukemia cells were incubated in suspension in RPMI 1640 medium (Nissui Seiyaku Co., Ltd., Tokyo, Japan) supplemented with 10% heat-inac tivated fetal bovine serum (HyClone Labora tories, Logan, UT, U.S.A.) and penicillin (50 units/ml)-streptomycin (50 fig/ml) (Flow Laboratories, North Ryde, Australia) at 37'C in a humidified atmosphere of 95% air/5% C02.
Cytotoxicity test: L1210 cells (4x104) were incubated with various concentrations of the test compound in 200 /d of medium in a 96-well microplate (Sumitomo Bakelite Co. Ltd., Tokyo, Japan) at 37°C for 2 hr. An antitumor drug was then added to the well, and the cells were incubated for 20 hr. 3H Thymidine (185 GBq/mmol, New England Nuclear Research Products, Boston, MA, U.S.A.) was added to each well at a final con centration of 18.5 kBq/ml, and the cultures were further incubated for 4 hr. The cells were trapped on a glass filter and washed with water with a cell harvester (Labo mash, Labo Science Co., Ltd., Tokyo, Japan), dried, and immersed in toluene scintillator. The radioac tivity on the filter was measured with a liquid scintillation counter (Packard 1500 or 4640 TRI-CARB, Packard Instruments, Downers Grove, IL, U.S.A.).
In the other experiment, L1210 cells (2x 106) were treated with the test compound in 4 ml of medium in a 12-well plate (Corning, New York, NY, U.S.A.) at 37'C for 2 hr. An antitumor drug was then added to the wells, and the cells were further incubated for 1 hr. The cells were washed twice with PBS by centrifugation and resuspended in fresh medium. Again the cells (4x104) were seeded onto a 96-well microplate in 200,ul of medium and incubated at 37°C for 20 hr. 3H-Thymi dine incorporation into the cells for 4 hr was then measured as mentioned above.
Cytotoxicity was assessed as the percen tage of inhibition of 3H-thymidine incorpora tion into the drug-treated cells to that of the drug-free control cells, in triplicate experi ments. was determined by a Bio Rad protein assay system using bovine serum albumin as the standard.
Alkaline elution method: Cellular DNA was radioactively labelled in L1210 cells by in cubation with 14C-thymidine (3.7 kBq/ml) at 37 °C for 20 hr. The cells were treated with the test compound for 2 hr. An antitumor drug was added to the culture, and the cells were incubated for 1 hr. The cells were washed twice with PBS to remove the drugs, resus pended in fresh drug-free medium and further incubated for 4 hr. Alkaline elution was per formed to determine DNA-DNA cross-links formation according to the previously de scribed method (7) .
Incorporation of FK973 into cells: L1210 cells ( 
Results
Effects of the test compounds on the cytotoxicity of FK973 against cells: We first examined whether MAO inhibitors would reduce the cytotoxicity of an antitumor drug against cells. After the cells were treated with an inhibitor for 2 hr, an antitumor drug was added to the cells, and the culture was further incubated with the inhibitor and the anti tumor drug for 24 hr. As shown in Fig. 2 , tranylcypromine reduced the inhibition of 3H-thymidine incorporation into the cells by FK973 (Fig. 2a) and MMC had clearly formed interstrand DNA-DNA cross-links in the cells. As shown in Fig. 4 , benzylamine dose-dependently in hibited the cross-link formation with FK973, but not that with MMC. Furthermore, the formation of interstrand DNA-DNA cross links with FK973 was inhibited by tranylcy promine, phenylethylamine and tyramine, but that with MMC was not (data not shown). None of the test compounds alone could cause the formation of interstrand DNA-DNA cross-links and DNA breaks in the cells. to examine the extent of the relationship be tween the cytotoxicity and the formation of the DNA-DNA cross-links. The cells were treated with benzylamine, tranylcypromine, phenylethylamine or tyramine at 37'C for 2 hr, and FK973 or MMC was added to the wells. The cells were incubated with FK973 or MMC and the test compound for 1 hr and washed to remove the drugs. The cells were further incubated in fresh medium for 24 hr. As shown in Fig. 5 , benzylamine dose-depend ently reduced the cytotoxicity of FK973 (Fig.  5a ), but not that of MMC (Fig. 5b) 
Discussion
In our previous study (7), we showed that FK973 was activated in the cytoplasm of cells to form interstrand DNA-DNA and DNA-pro tein cross-links, which may be involved in the cytotoxic mechanism of the drug. In this study, we examined the mechanisms by which FK973 is activated after being incor porated in the cytoplasm. First, the effects of the compounds that affect MAO activity on the cytotoxicity of FK973 against in vitro cultured L1210 cells were examined. The cytotoxicity of FK973 was reduced by tranylcypromine, a MAO inhibitor, but was not by other MAO inhibitors, iproniazid, nialamide and pargyline.
Since there are several reports that MAO is important for drug metabolism (21-23), the fact that tranylcy promine reduced the cytotoxicity of FK973 indicates that FK973 might be activated in the cytoplasm by drug metabolic systems related to MAO. Thus, the effects of the substrates of MAO on the cytotoxicity of FK973 were ex amined. The treatment of cells with benzyl amine, phenylethylamine and tyramine re duced the cytotoxicity of FK973. Phenyl propylamine had only a slight effect on the cytotoxicity of FK973, and phenylbutylamine had no effect. From this we can assume that not all MAO substrates reduce the cytotoxicity of FK973. On the other hand, iproniazid could not reduce the cytotoxicity of FK973, al though iproniazid perfectly inhibited the ac tivity of MAO in L1210 cells. It is reported that MAO inhibitors have numerous effects unre lated to enzyme inhibition. Thus, the reduc tion of the cytotoxicity of FK973 by an inhibi tor and substrates of MAO would not neces sarily stem from the inhibition of MAO ac tivity. Furthermore, the fact that tranylcypro mine, benzylamine, phenylethylamine and tyramine showed no effect on the incorpora tion of 14C-FK973 into the cells would sug gest that these compounds selectively reduce the cytotoxicity of FK973 without affecting its transport into the cells. side chain, phenylpropylamine, had only a slight effect on the cytotoxicity of FK973, and the compounds with no and four carbons in their side chains, aniline and phenylbutyl amine, respectively, had no effect. These results would suggest that FK973 is activated by a specific enzyme(s) with catalytic ac tivity on a series of common structures in the cytoplasm.
FK973 and MMC have a car bamoyl moiety and an aziridine ring in their molecules.
It is known that the carbamoyl moiety and aziridine ring of MMC bind DNA after MMC is easily activated by the reduc tion of its quinone ring in the cytoplasm (15, 16, 18) . Thus, the carbamoyl moiety and aziridine ring of FK973 may be related to its binding sites with DNA in the cells. However, since FK973 has no quinone ring in its struc ture, its structure seems to be rather stable. Thus, the specific activation of the binding sites of FK973 with DNA may be necessary. A detailed study of the mode of activation of FK973 in the cytoplasm is needed. In summary, the present results suggest that FK973 is activated by some drug met abolic systems in the cytoplasm to form interstrand DNA-DNA cross-links, which are involved in the cytotoxic effects of FK973. 
